Home ••• Newswires by Industry • Countries • U.S. States • World Media Directory

Pharmaceutical Industry News ••• Topics • Countries • U.S. States

Renal Cell Carcinoma Drugs News Monitoring

Get by Email • RSS

Published on Jun 14, 2025

Zanzalintinib/Nivolumab Combo Shows Promise in Advanced RCC

The combination of zanzalintinib and nivolumab (Opdivo) has demonstrated encouraging effectiveness and acceptable tolerability in individuals with previously untreated stage 4 renal cell carcinoma (RCC). Initial findings from an expansion cohort of the …

Source: Targeted Oncology - Pending
Published on Jun 14, 2025

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

“Tivozanib is regarded as one of the better tolerated VEGF TKIs, and we saw a similar toxicity profile in either of the arms that we looked at. The most common [adverse] effect observed was hypertension; however, it was [mostly] low grade and manageable.” …

Source: OncLive - Pending
Published on 13:16 GMT

Are you always stressed? Oncologist says ‘hypertension can cause kidney cancer’

In an interview with HT Lifestyle, Dr Pushpinder Gulia, director of surgical oncology and robotic oncosurgery, CK Birla Hospital, Gurugram said, “Controlling hypertension isn’t just about preventing heart disease; it’s also a key step in reducing your risk …

Source: Hindustan Times - Indeterminate
Published on Jun 12, 2025

A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment

At the 2025 ASCO Annual Meeting, key updates in the treatment of various cancers were shared with physicians and patients, including the treatment of newly diagnosed clear cell renal cell carcinoma, a type of kidney cancer. One such update for this patient …

Source: Cure Today - Neutral
Published on Jun 12, 2025

Pembrolizumab Extends Survival in RCC: 5-Year Study Results

Adjuvant treatment with pembrolizumab (Keytruda) continues to demonstrate consistent benefits in both overall survival (OS) and disease-free survival (DFS) when compared to a placebo for individuals with clear cell renal cell carcinoma (ccRCC). This …

Source: Targeted Oncology - Pending
Published on Jun 12, 2025

Tivozanib Shows Efficacy in Pretreated Metastatic RCC

Clinical activity was reported in patients with metastatic renal cell carcinoma (RCC) who received tivozanib (Fotivda) monotherapy following prior treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) or a tyrosine kinase inhibitor (TKI) plus an …

Source: Cancer Network - New Jersey - Pending
Published on Jun 11, 2025

The Synergistic and Attenuated Mechanism of Action of the Xihuang Pill in Dual Immunotherapy After Stenting for Advanced ...

Introduction Cholangiocarcinoma (CCA) is a malignant tumor originating from the epithelial cells of the bile duct. A study showed that the global incidence of CCA increased by 25% between 2007 and 2017.1 The incidence of CCA in China has also increased …

Source: Dove Medical Press - Neutral
Published on Jun 14, 2025

Cancer cells exploit alternative pathway to gather antioxidant lipids and evade cell death

Baku, June 14, AZERTAC Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to survive stress, according to MedicaXpress …

Source: Azertag - Gov't Propaganda
Published on Jun 13, 2025

Ipi/Nivo Combo Extends Survival in Advanced Kidney Cancer

Final data from the CheckMate-214 phase 3 trial (NCT02231749) show that first-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continues to demonstrate improved survival and lasting response benefits when compared to sunitinib (Sutent) in patients with …

Source: Targeted Oncology - Pending
Published on Jun 13, 2025

Tumors Use Non-Traditional Pathway To Acquire Antioxidants

Register for free to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. Scientists have discovered tumors can tap a …

Source: Technology Networks - Neutral
Published on Jun 12, 2025

Jad Chahoud, MD, on first-line zanzalintinib plus nivolumab for advanced ccRCC

The combination of zanzalintinib plus nivolumab (Opdivo) demonstrated encouraging preliminary activity with manageable safety in patients with previously-untreated advanced or metastatic clear cell renal cell carcinoma (ccRCC), according to data from an …

Source: Urology Times - Pending
Published on Jun 11, 2025

Glycosaminoglycan-driven lipoprotein uptake protects tumours from ferroptosis

Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V. & Fendt, S.-M. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev. Cell 56, 1363–1393 (2021). Article CAS PubMed Google Scholar Riscal, R. et al. Cholesterol …

Source: Nature - Neutral
Published on Jun 12, 2025

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041 OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: …

Distribution channels:
Published on Jun 12, 2025

Children's Research Institute Scientists Uncover Unique Pathway Tumors Use to Acquire Antioxidant Lipids

Newswise — DALLAS – June 11, 2025 – Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins – molecules that transport fat in blood – which enriches cancer cells with an antioxidant shield to survive stress, according to …

Source: Newswise - Neutral
Published on Jun 12, 2025

Telix shares push higher on investor day update

Image source: Getty Images Telix Pharmaceuticals Ltd (ASX: TLX) shares are rising on Thursday morning. At the time of writing, the radiopharmaceuticals company's shares are up 1% to $25.88. This follows the release of a wide-ranging update at its …

Source: The Motley Fool Australia - Neutral
Published on 16:45 GMT

Waterlogging in Sassoon Hospital Basement Poses Health Risk

The basement parking area of the newly constructed building at Sassoon General Hospital has become a health and structural hazard due to severe waterlogging caused by poor waterproofing and construction defects. The issue is reportedly creating ideal …

Source: Pune Mirror - Pending
Published on Jun 14, 2025

Umahi defends Tinubu, says North has 52% of legacy projects

The Minister of Works, David Umahi has faulted claims by some Northern Elders who said the Federal Government is undertaking more road projects in the Southern geo-political zone of the country. The minister said such claim which according to him is …

Source: Punch - Indeterminate

16 days 16:13:58

Featured Releases

Got News to Share? · Submit · See All

Published on June 15, 2025 - 14:00 GMT

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in West Pharmaceutical Services, ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST). Such investors are advised to contact Danielle Peyton at …

Distribution channels: Consumer Goods, Law ...
Published on June 15, 2025 - 14:33 GMT

WST 重要截止日期：全美審訊法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 West Pharmaceutical Services, Inc. 投資者在對 WST 提出證券集體訴訟的重要截止日期前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒在 2023 年 2 月 16 日至 2025 年 2 月 12 日（包括首尾兩日，下稱「集體訴訟期」）期間購買了 West Pharmaceutical Services, Inc. (NYSE: WST) 普通股之人士注意，重要的首席原告截止日期為 2025 年 7 月 7 日。影響：如果您在集體訴訟期間購買 West …

Distribution channels: Consumer Goods, Law ...

Published on June 15, 2025 - 14:33 GMT

WST IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive ( …

Distribution channels: Consumer Goods, Law ...
Published on June 15, 2025 - 14:00 GMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw …

Distribution channels: Consumer Goods, Law ...

Published on June 15, 2025 - 14:00 GMT

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. …

Distribution channels: Consumer Goods, Law ...
Published on June 15, 2025 - 15:22 GMT

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 15, 2025 - 15:22 GMT

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes ...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 15, 2025 - 15:21 GMT

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Got news to share? Submit it now.

Load more pharmaceuticals news or search news using your own keywords. There are 822,454,709 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country

Pharmaceutical Industry News by U.S. State

Pharmaceutical Industry News Topics

Online News Publications

World News Report

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter

Create RSS Feed

NewsPlugin for WordPress

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire

Events

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 05/18/2025

World Media Directory

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All

Published on June 15, 2025 - 12:13 GMT

Mindworks NLP Offers a Smoking Cessation Group Hypnosis Live Event in Bellevue – June 21

Mindworks NLP announces a public group hypnosis seminar on June 21 to help participants quit smoking using powerful subconscious change techniques. BELLEVUE, WA, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- In a time when public health and …

Distribution channels: Companies, Culture, Society & Lifestyle ...
Published on June 15, 2025 - 12:06 GMT

Redefining Fabry Disease Care: Gene Therapy and Long-Acting ERT Prepare to Disrupt Status Quo | Competitive Intellignece

Fabry disease treatment is advancing rapidly with gene therapies and next-gen ERTs promising durable efficacy, reduced burden, and broader mutation coverage. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Fabry Disease, a rare, X …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 15, 2025 - 12:06 GMT

Rewriting the Playbook in MPS I: CNS-Penetrant ERTs and Gene Therapies Usher in a New Treatment Era | CI Insights

Emerging CNS‑targeting ERTs and gene therapies for MPS I show promise for neurocognitive benefits, reduced treatment burden, and better outcomes. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Mucopolysaccharidosis type I (MPS I) …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 15, 2025 - 12:06 GMT

Hunter Syndrome Therapeutics Evolve: Novel CNS-Targeting Therapies Set to Challenge Elaprase’s Market Monopoly

New CNS-penetrant therapies and gene therapies are poised to transform the Hunter Syndrome landscape, ending Elaprase’s long-standing treatment dominance. AUSTIN, TX, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Hunter Syndrome ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 15, 2025 - 04:30 GMT

Thorncrest Dental Brings Advanced Laser Dentistry to Etobicoke with Picasso Soft Tissue Laser

ETOBICOKE, ONTARIO, CANADA, June 15, 2025 /⁨EINPresswire.com⁩/ -- Thorncrest Dental is proud to introduce the Picasso Soft Tissue Laser, a cutting-edge addition to its suite of dental technologies, now available to patients in the Etobicoke community. This …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 15, 2025 - 15:22 GMT

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 15, 2025 - 15:22 GMT

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes ...

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 15, 2025 - 15:21 GMT

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 15, 2025 - 03:00 GMT

Tom Jackobs Offers Fractional Sales Management for Heart-Led Wellness Practices

New service helps mission-driven businesses improve sales performance without building a full in-house sales team. LOS ANGELES, CA, UNITED STATES, June 15, 2025 /⁨EINPresswire.com⁩/ -- Tom Jackobs, international sales strategist, is now offering …

Distribution channels: Book Publishing Industry, Business & Economy ...
Published on June 15, 2025 - 14:45 GMT

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in ...

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 15, 2025 - 12:00 GMT

New national report reveals critical gaps in asthma and COPD care

A new NRAP report has highlighted persistent and widespread gaps in the care of people with asthma and chronic obstructive pulmonary disease (COPD) across England and Wales, calling on integrated care boards and local health boards to mandate all eligible …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 15, 2025 - 12:00 GMT

RCP statement on Air India crash

RCP president, Dr Mumtaz Patel, said: ‘We are devastated by the plane crash in India today and the many lives it has claimed. Our thoughts and prayers are with everyone affected by this tragic incident. ‘We are directly contacting all our RCP members in …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 15, 2025 - 12:00 GMT

Latest ‘Focus on physicians’ survey closes with over 2000 responses from doctors across the UK

The 2025 ‘Focus on physicians’ survey – a joint project between the Royal College of Physicians (RCP), the Royal College of Physicians and Surgeons of Glasgow (RCPSG) and the Royal College of Physicians of Edinburgh (RCPE) – has now closed. The ‘Focus on …

Distribution channels: Healthcare & Pharmaceuticals Industry
Published on June 15, 2025 - 11:45 GMT

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ...

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelumab – – Supports potentially differentiated profile of …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...
Published on June 15, 2025 - 11:11 GMT

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth

Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle- …

Distribution channels:
Published on June 14, 2025 - 16:42 GMT

Blue Sky Scrubs Celebrates World Wind Day: Championing Clean Energy for a Healthier Planet

Blue Sky Medical Scrubs and Scrub Caps Celebrates World Wind Day: Championing Clean Energy for a Healthier Planet AUSTIN, TX, UNITED STATES, June 14, 2025 /⁨EINPresswire.com⁩/ -- In celebration of World Wind Day, Blue Sky Scrubs proudly joins the …

Distribution channels: Culture, Society & Lifestyle, Environment ...
Published on June 14, 2025 - 16:38 GMT

Cherry Blossoms and The Other Side, A Poetic Journey Through Grief and Beyond

LAWRENCE, MA, UNITED STATES, June 14, 2025 /⁨EINPresswire.com⁩/ -- Acclaimed writer and visual dramatist Dennis Mullings presents a powerful double release with Cherry Blossoms and The Other Side, two moving and visually arresting plays that navigate the …

Distribution channels: Book Publishing Industry, Culture, Society & Lifestyle ...
Published on June 14, 2025 - 16:28 GMT

ICN elects new President, José Luis Cobos Serrano and a new Board of Directors

ICN announces Dr José Luis Cobos Serrano as its 30th President at its Congress in Helsinki HELSINKI, FINLAND, June 14, 2025 /⁨EINPresswire.com⁩/ -- At the closing ceremony of ICN Congress 2025, ICN announced that it has elected Dr José Luis Cobos …

Distribution channels: Healthcare & Pharmaceuticals Industry, Human Rights ...
Published on June 14, 2025 - 14:48 GMT

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in ...

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 14, 2025 - 14:42 GMT

ThinkCareBelieve: Week 21 of America's Progress under President Trump

Washington D.C., June 14, 2025 (GLOBE NEWSWIRE) -- You can find the article here: https://thinkcarebelieve.blog/2025/06/14/week-21-of-americas-progress-under-president-trump/ ThinkCareBelieve has published an article on the …

Distribution channels: Book Publishing Industry, Healthcare & Pharmaceuticals Industry ...